Anzeige
Erschienen in:
15.07.2021 | Original Article
The impact of CD33/CD34 ratio in the prognosis of myelodysplastic syndrome treated with azacitidine for first-line therapy
Erschienen in: Journal of Hematopathology | Ausgabe 3/2021
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Azacitidine (AZA), a hypomethylating agent, is the standard treatment for patients with myelodysplastic syndromes (MDS). However, responses are generally transient in approximately 50% of patients. Cytomorphology and immunophenotyping are widely used in the treatment of MDS. Therefore, the present study investigated the relationship between immunophenotyping and the outcomes of MDS patients administered AZA as first-line therapy.
Methods
We retrospectively examined the relationship between immunophenotyping and the outcomes of 118 MDS patients administered AZA as first-line therapy.
Results
The response to AZA was poorer in patients with a CD33/CD34 ratio > 1 than in those with a CD33/CD34 ratio < 1. Univariate and multivariate analyses identified higher serum LDH levels, higher risk IPSS-R, and a CD33/CD34 ratio > 1 as independent adverse prognostic factors for overall survival. A Kaplan–Meier analysis showed that a CD33/CD34 ratio > 1 was associated with poor survival.
Conclusion
In the present study, a CD33/CD34 ratio > 1 in blast cells was associated with poor survival in MDS patients administered AZA as first-line therapy.